Colloidal submicron-particle curcumin exhibits high absorption efficiency—a double-blind, 3-way crossover study

Journal of Nutritional Science and Vitaminology

Volumn 61, Issue 1, 2015, Pages 37-44

  Sunagawa, Yoichi ^a,b,c   Hirano, Sae ^a,d   Katanasaka, Yasufumi ^a,b,c   Miyazaki, Yusuke ^a   Funamoto, Masafumi ^a   Okamura, Nobuko ^a   Hojo, Yuya ^a   Suzuki, Hidetoshi ^a   Doi, Osamu ^b   Yokoji, Tsunehiro ^b   Morimoto, Eriko ^b   Takahashi, Tsukasa ^e   Ozawa, Hitomi ^e   Imaizumi, Atsushi ^e   Ueno, Morio ^f   Kakeya, Hideaki ^g   Shimatsu, Akira ^c   Wada, Hiromichi ^c   Hasegawa, Koji ^c   Morimoto, Tatsuya ^a,b,c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d SHIZUOKA SAISEIKAI GENERAL HOSPITAL   (Japan)

^e Theravalues Corporation   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

Colloidal submicron particles; Curcumin; Drug delivery system; Human; Plasma levels

Indexed keywords

CURCUMIN; COLLOID; MICROCAPSULE; PLANT EXTRACT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; BIOAVAILABILITY; BLOOD; CHEMISTRY; CLINICAL TRIAL; COLLOID; COMPARATIVE STUDY; CURCUMA; DOSE RESPONSE; INTESTINE ABSORPTION; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PHYTOTHERAPY; YOUNG ADULT;

CURCUMA LONGA;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; COLLOIDS; CROSS-OVER STUDIES; CURCUMA; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; PARTICLE SIZE; PHYTOTHERAPY; PLANT EXTRACTS; YOUNG ADULT;

EID: 84929746463     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.61.37     Document Type: Article

References (45)

1. Metzler M, Pfeiffer E, Schulz SI, Dempe JS. 2013. Curcumin uptake and metabolism. Biofactors 39: 14–20.
2. Grynkiewicz G, Ślifirski P. 2012. Curcumin and curcuminoids in quest for medicinal status. Acta Biochim Pol 59: 201–212.
3. Aggarwal BB, Yuan W, Li S, Gupta SC. 2013. Curcuminfree turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Mol Nutr Food Res 57: 1529–1542.
4. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. 2013. Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol Nutr Food Res 57: 1510–1528.
5. Goel A, Kunnumakkara AB, Aggarwal BB. 2008. Curcumin as “Curecumin”: From kitchen to clinic. Biochem Pharmacol 75: 787–809.
6. Shimatsu A, Kakeya H, Imaizumi A, Morimoto T, Kanai M, Maeda S. 2012. Clinical application of “curcumin,” a multi-functional substance. Anti-Aging Med 9: 75–83.
7. Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE, Rimbach G. 2012. Curcumin—from molecule to biological function. Angew Chem Int Ed Engl 51: 5308–5332.
8. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. 1999. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 47: 4297–4300.
9. Lopez-Lazaro M. 2008. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52: S103-S127.
10. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. 2008. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118: 868–878.
11. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. 2011. A natural p300-specifi c histone acetyltransferase inhibitor, curcumin, in addition to angiotensin converting enzyme inhibitor exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 75: 2151–2159.
12. Thiyagarajan M, Sharma SS. 2004. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 74: 969–985.
13. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. 1980. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs and monkeys. Indian J Exp Biol 18: 73–75.
14. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. 2008. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17: 1411–1417.
15. Sharma RA, Steward WP, Gescher AJ. 2007. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 595: 453–470.
16. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807–818.
17. Henrotin Y, Priem F, Mobasheri A. 2013. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. Springerplus 2: 56.
18. Fang M, Jin Y, Bao W, Gao H, Xu M, Wang D, Wang X, Yao P, Liu L. 2012. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int J Nanomedicine 7: 5395–5404.
19. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353–356.
20. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. 2008. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (BiocurcumaxTM), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70: 445–449.
21. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. 2011. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74: 664–669.
22. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. 2011. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34: 660–665.
23. Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T, Katanasaka Y, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K, Morimoto T. 2012. A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rat. Biol Pharm Bull 35: 139–144.
24. Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. 2013. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 71: 1521–1530.
25. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T. 2012. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 69: 65–70.
26. Akazawa N, Choi Y, Miyaki A, Tanabe Y, Sugawara J, Ajisaka R, Maeda S. 2012. Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr Res 32: 795–799.
27. Sugawara J, Akazawa N, Miyaki A, Choi Y, Tanabe Y, Imai T, Maeda S. 2012. Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: pilot study. Am J Hypertens 25: 651–656.
28. Chandran B, Goel A. 2012. A randomized, pilot study to assess the effi cacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 26: 1719–1725.
29. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. 2010. Efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 15: 337–344.
30. Morimoto T, Sunagawa Y, Katanasaka Y, Hirano S, Namiki M, Watanabe Y, Suzuki H, Doi O, Suzuki K, Yamauchi M, Yokoji T, Miyoshi-Morimoto E, Otsuka Y, Hamada T, Imaizumi A, Nonaka Y, Fuwa T, Teramoto T, Kakeya H, Wada H, Hasegawa K. 2013. Drinkable preparation of theracurmin exhibits high absorption efficiency—A single-dose, double-blind, 4-way crossover study—. Biol Pharm Bull 36: 1708–1714.
31. Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, Sarkar FH. 2010. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem 10: 372–387.
32. Benny M. 2006. Antony B. Bioavailability of Biocurcumax (BCM-095TM). Spice India 19: 11–15.
33. Barry J, Fritz M, Brender JR, Smith PE, Lee DK, Ramamoorthy A. 2009. Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J Am Chem Soc 131: 4490–4498.
34. Di Pierro F, Rapacioli G, Di Maio EA, Appendino G, Franceschi F, Togni S. 2013. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva), nimesulide, and acetaminophen. J Pain Res 6: 201–205.
35. Ledda A, Belcaro G, Dugall M, Luzzi R, Scoccianti M, Togni S, Appendino G, Ciammaichella G. 2012. Meriva, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study. Panminerva Med 54: 17–22.
36. Mazzolani F, Togni S. 2013. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. Clin Ophthalmol 7: 939–945.
37. Mazzolani F. 2012. Pilot study of oral administration of a curcumin-phospholipid formulation for treatmentof central serous chorioretinopathy. Clin Ophthalmol 6: 801–806.
38. Steigerwalt R, Nebbioso M, Appendino G, Belcaro G, Ciammaichella G, Cornelli U, Luzzi R, Togni S, Dugall M, Cesarone MR, Ippolito E, Errichi BM, Ledda A, Hosoi M, Corsi M. 2012. Meriva, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med 54: 11–16.
39. Allegri P, Mastromarino A, Neri P. 2010. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol 4: 1201–1206.
40. Handran B, Goel A. 2012. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 26: 1719–1725.
41. Deepa Das A, Balan A, Sreelatha KT. 2012. Comparative study of the efficacy of curcumin and turmeric as chemopreventative agents in oral submucous fibrosis: a clinical and histopathological evaluation. J Indian Acad Oral Med Radiol 22: 88–92.
42. Wahlström B, Blennow G. 1978. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43: 86–92.
43. Ravindranath V, Chandrasekhara N. 1980. Absorption and tissue distribution of curcumin in rats. Toxicology 16: 259–265.
44. Holder GM, Plummer JL, Ryan AJ. 1978. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy- 3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8: 761–768.
45. Basnet P, Skalko-Basnet N. 2011. Curcumin: an antiinflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16: 4567–4598.